Clinical Trials Browser

Phase 1/2 × abiraterone × 90 days × Clear all

Bulbo-Spinal Atrophy, X-Linked

NCT07226986 2026-06-02

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT06863272 2026-05-29

IDeate-Prostate02

Phase 1/2 Recruiting

360 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

TulmiSTAR-02

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

IDeate-Prostate02

CELLO-1